|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed-maturity securities available-for-sale, at fair value (amortized cost: $3,611,960 in 2026 and $3,378,618 in 2025) | ||||||||||||||||||||
| Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,036,619 in 2026 and $1,153,047 in 2025) | ||||||||||||||||||||
| Short-term investments available-for-sale, at fair value (amortized cost: $276 in 2023) | ||||||||||||||||||||
| Short-term investments available-for-sale, at fair value (amortized cost: $4,953 in 2026) | ||||||||||||||||||||
| Equity securities, at fair value (historical cost: $20,624 in 2026 and $20,501 in 2025) | ||||||||||||||||||||
| Trading securities, at fair value (cost: $32,813 in 2026 and $13,084 in 2025) | ||||||||||||||||||||
| Policy loans and other invested assets | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Reinsurance recoverables | ||||||||||||||||||||
| Deferred policy acquisition costs, net | ||||||||||||||||||||
| Renewal commissions receivable | ||||||||||||||||||||
| Agent balances, due premiums and other receivables | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible asset | ||||||||||||||||||||
| Income taxes | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Assets from discontinued operations entities | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders' equity: | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Unearned and advance premiums | ||||||||||||||||||||
| Policy claims and other benefits payable | ||||||||||||||||||||
| Other policyholders’ funds | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Surplus note | ||||||||||||||||||||
| Income taxes | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Payable under securities lending | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Liabilities from discontinued operations entities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock ($0.01 par value; authorized 500,000 shares in 2026 and 2025; issued and outstanding 30,898 shares in 2026 and 31,810 shares in 2025) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of income tax: | ||||||||||||||||||||
| Effect of change in discount rate assumptions on the liability for future policy benefits | ||||||||||||||||||||
| Unrealized foreign currency translation gains (losses) | ||||||||||||||||||||
| Net unrealized investment gains (losses) on available-for-sale securities | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
